Sutro Biopharma (NASDAQ:STRO) said on Thursday that, under its portfolio review, the company has decided to advance its ...

BofA downgraded Sutro Biopharma (STRO) to Underperform from Buy with a price target of $1, down from $11, following the company’s announcement ...

John Arena is interim president of global pharma services at Cencora, managing a team that offers a broad range of solutions ...

Fintel reports that on March 14, 2025, B of A Securities downgraded their outlook for Sutro Biopharma (NasdaqGM:STRO) from ...

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or ...

MoonLake, a clinical-stage biopharma company developing immunology therapeutics, was created by an April 2022 merger with ...

Sutro completed its review as it widened its loss and posted lower revenue in 2024. The company posted a loss of $227.5 million last year, compared with a loss of $106.8 million in 2023. On a ...

As we reflect on five years of COVID-19, it’s clear that the impacts are still unfolding. The life sciences—and we as ...

StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research ...

Benitec Biopharma Inc. (NASDAQ:BNTC – Get Free Report) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $11.29 and traded as high as $13.45.

Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Biopharma companies require optimal clone yields to ensure maximum concentration and effectiveness of these therapeutic ...